The FDA has granted Breakthrough Therapy designation to BPL-003 (mebufotenin benzoate) nasal spray for adults with treatment-resistant depression.

Longitudinal data shows increasing or high addictive use of social media and mobile phones in adolescents significantly raises the risk of suicidal behaviors and ideation.

The FDA has approved Uzedy (risperidone) as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults.

(HealthDay News) — Brief bouts of exercise spread throughout the day (“exercise snacks”) improve cardiorespiratory fitness in physically inactive adults, according to a review published online in the ...

(HealthDay News) — The risk for amyotrophic lateral sclerosis (ALS) is higher in the 2 years after a traumatic brain injury (TBI), according to a study published online Oct. 2 in JAMA Network Open.

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for CTx-1301 for the treatment of attention deficit/hyperactivity disorder (ADHD) in children and adults.

The researchers found that fewer patients receiving BCBT than PCT attempted suicide during follow-up. (HealthDay News) — Among U.S. military personnel and veterans reporting recent suicidal ideation ...

There was evidence of a harmful effect of tramadol on serious adverse events (odds ratio, 2.13), which was mainly due to a higher proportion of cardiac events and neoplasms. (HealthDay News) — ...